{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PIWORLD Investor Podcasts","title":"Open Orphan (ORPH) presentation at ShareSoc March 2020","html":"","width":"100%","height":180,"duration":2283,"description":"This video can be seen at: https://www.piworld.co.uk/2020/03/16/open-orphan-orph-presentation-at-sharesoc-march-2020/\n \nBy Cathal Friel, Exec Chair\nFriel gives an overview of Open Orphan, how it was formed, the business, hVIVO and its work with virus testing, plus comments on COVID-19.\nIntroduction – 00:18Open Orphan management – 03:00History and acquisitions – 04:15High value & longer-term contracts – 08:32Open Orphan – 09:22Genomic database – 10:13hVIVO viral challenge studies, etc – 10:33Cross-selling – 17:45Pipeline – 18:42Cost reduction programme – 19:42Development assets – 20:01COVID-19 – 21:12\nQ&A – 29:15\nOpen Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.","thumbnail_url":"https://img.transistorcdn.com/oB5fNE4aIAia_YyTCKvE1PzrZQaD1Fjo_P7m7T9Aw_Y/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kOTJi/ODBiMzBmOGFhZWJi/MWEzYThkMzAyNmZm/MTdjZi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}